Wedbush Reaffirms “Outperform” Rating for Voyager Therapeutics (NASDAQ:VYGR)

Wedbush reiterated their outperform rating on shares of Voyager Therapeutics (NASDAQ:VYGR) in a research note released on Wednesday morning,Benzinga reports.

Other equities analysts also recently issued reports about the stock. Canaccord Genuity Group reaffirmed a “buy” rating and set a $14.00 price objective on shares of Voyager Therapeutics in a research note on Thursday, November 14th. HC Wainwright reaffirmed a “buy” rating and set a $30.00 price objective on shares of Voyager Therapeutics in a research note on Monday, March 3rd. Citigroup assumed coverage on shares of Voyager Therapeutics in a research note on Monday, December 2nd. They set a “buy” rating and a $12.00 price objective for the company. StockNews.com downgraded shares of Voyager Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, December 13th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Voyager Therapeutics in a research note on Wednesday. One analyst has rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $15.08.

Voyager Therapeutics Stock Up 2.3 %

NASDAQ VYGR opened at $4.06 on Wednesday. The company has a 50-day simple moving average of $4.95 and a two-hundred day simple moving average of $5.87. Voyager Therapeutics has a 12-month low of $3.56 and a 12-month high of $10.66. The firm has a market cap of $221.78 million, a price-to-earnings ratio of 5.72 and a beta of 0.99.

Voyager Therapeutics (NASDAQ:VYGR) last issued its quarterly earnings data on Tuesday, March 11th. The company reported ($0.59) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.24). The firm had revenue of $4.39 million for the quarter, compared to the consensus estimate of $16.58 million. Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. During the same period last year, the company posted $1.25 earnings per share. Equities analysts expect that Voyager Therapeutics will post -0.91 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Voyager Therapeutics news, COO Robin Swartz sold 6,500 shares of the company’s stock in a transaction dated Monday, December 23rd. The shares were sold at an average price of $5.65, for a total value of $36,725.00. Following the sale, the chief operating officer now owns 112,328 shares in the company, valued at approximately $634,653.20. This represents a 5.47 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders sold a total of 10,778 shares of company stock valued at $58,548 over the last three months. Corporate insiders own 4.53% of the company’s stock.

Institutional Investors Weigh In On Voyager Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of VYGR. Cubist Systematic Strategies LLC purchased a new stake in Voyager Therapeutics in the fourth quarter worth about $29,000. Tower Research Capital LLC TRC grew its holdings in Voyager Therapeutics by 133.4% in the fourth quarter. Tower Research Capital LLC TRC now owns 5,383 shares of the company’s stock worth $31,000 after purchasing an additional 3,077 shares during the period. Picton Mahoney Asset Management grew its holdings in Voyager Therapeutics by 71.1% in the fourth quarter. Picton Mahoney Asset Management now owns 5,883 shares of the company’s stock worth $33,000 after purchasing an additional 2,444 shares during the period. Oxford Asset Management LLP purchased a new stake in Voyager Therapeutics in the fourth quarter worth about $60,000. Finally, Intech Investment Management LLC purchased a new stake in Voyager Therapeutics in the third quarter worth about $74,000. Hedge funds and other institutional investors own 48.03% of the company’s stock.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.